Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 39

1.

THE CANCER HYPOTHESIS OF PULMONARY ARTERIAL HYPERTENSION: THE NEXT TEN YEARS.

Condon D, Agarwal S, Chakraborty A, de Jesus Perez VA.

Am J Physiol Lung Cell Mol Physiol. 2020 Mar 18. doi: 10.1152/ajplung.00057.2020. [Epub ahead of print] No abstract available.

PMID:
32186209
2.

Mural Cell SDF1 Signaling is Associated with the Pathogenesis of Pulmonary Arterial Hypertension.

Yuan K, Liu Y, Zhang Y, Nathan A, Tian W, Yu J, Sweatt AJ, Shamskhou EA, Condon D, Chakraborty A, Agarwal S, Auer N, Zhang S, Wu JC, Zamanian RT, Nicolls MR, de Jesus Perez VA.

Am J Respir Cell Mol Biol. 2020 Feb 21. doi: 10.1165/rcmb.2019-0401OC. [Epub ahead of print]

PMID:
32084325
3.

Diagnosis and Management of Pulmonary Hypertension in the Modern Era: Insights from the 6th World Symposium.

Thomas CA, Anderson RJ, Condon DF, de Jesus Perez VA.

Pulm Ther. 2019 Nov 29. doi: 10.1007/s41030-019-00105-5. [Epub ahead of print] Review.

PMID:
32048239
4.

Methamphetamine use association with pulmonary diseases: a retrospective investigation of hospital discharges in California from 2005 to 2011.

Tsai H, Lee J, Hedlin H, Zamanian RT, de Jesus Perez VA.

ERJ Open Res. 2019 Oct 15;5(4). pii: 00017-2019. doi: 10.1183/23120541.00017-2019. eCollection 2019 Oct.

5.

Beyond the Lungs: Systemic Manifestations of Pulmonary Arterial Hypertension.

Nickel NP, Yuan K, Dorfmuller P, Provencher S, Lai YC, Bonnet S, Austin ED, Koch CD, Morris A, Perros F, Montani D, Zamanian RT, de Jesus Perez VA.

Am J Respir Crit Care Med. 2020 Jan 15;201(2):148-157. doi: 10.1164/rccm.201903-0656CI.

PMID:
31513751
6.

EpiHope for the Treatment of Pulmonary Arterial Hypertension: Selective versus Nonselective BET Inhibition.

Pullamsetti SS, de Jesus Perez VA.

Am J Respir Crit Care Med. 2019 Nov 1;200(9):1188-1190. doi: 10.1164/rccm.201906-1235LE. No abstract available.

PMID:
31419389
7.

The 6th World Symposium on Pulmonary Hypertension: what's old is new.

Condon DF, Nickel NP, Anderson R, Mirza S, de Jesus Perez VA.

F1000Res. 2019 Jun 19;8. pii: F1000 Faculty Rev-888. doi: 10.12688/f1000research.18811.1. eCollection 2019. Review.

8.

Hydrogel-based delivery of Il-10 improves treatment of bleomycin-induced lung fibrosis in mice.

Shamskhou EA, Kratochvil MJ, Orcholski ME, Nagy N, Kaber G, Steen E, Balaji S, Yuan K, Keswani S, Danielson B, Gao M, Medina C, Nathan A, Chakraborty A, Bollyky PL, De Jesus Perez VA.

Biomaterials. 2019 May;203:52-62. doi: 10.1016/j.biomaterials.2019.02.017. Epub 2019 Feb 22.

PMID:
30852423
9.

Low-grade albuminuria in pulmonary arterial hypertension.

Nickel NP, de Jesus Perez VA, Zamanian RT, Fessel JP, Cogan JD, Hamid R, West JD, de Caestecker MP, Yang H, Austin ED.

Pulm Circ. 2019 Apr-Jun;9(2):2045894018824564. doi: 10.1177/2045894018824564.

10.

Loss of Endothelium-Derived Wnt5a Is Associated With Reduced Pericyte Recruitment and Small Vessel Loss in Pulmonary Arterial Hypertension.

Yuan K, Shamskhou EA, Orcholski ME, Nathan A, Reddy S, Honda H, Mani V, Zeng Y, Ozen MO, Wang L, Demirci U, Tian W, Nicolls MR, de Jesus Perez VA.

Circulation. 2019 Apr 2;139(14):1710-1724. doi: 10.1161/CIRCULATIONAHA.118.037642.

11.

EMAPII: A Key Player in HIV-Nef-induced Pulmonary Vasculopathy.

Shamskhou EA, Verghese L, Yuan K, de Jesus Perez VA.

Am J Respir Cell Mol Biol. 2019 Mar;60(3):257-258. doi: 10.1165/rcmb.2018-0327ED. No abstract available.

12.

New and Emerging Therapies for Pulmonary Arterial Hypertension.

Spiekerkoetter E, Kawut SM, de Jesus Perez VA.

Annu Rev Med. 2019 Jan 27;70:45-59. doi: 10.1146/annurev-med-041717-085955. Epub 2018 Sep 14. Review.

PMID:
30216732
13.

Drug-induced pulmonary arterial hypertension: a primer for clinicians and scientists.

Orcholski ME, Yuan K, Rajasingh C, Tsai H, Shamskhou EA, Dhillon NK, Voelkel NF, Zamanian RT, de Jesus Perez VA.

Am J Physiol Lung Cell Mol Physiol. 2018 Jun 1;314(6):L967-L983. doi: 10.1152/ajplung.00553.2017. Epub 2018 Feb 8.

14.

Emerging role of angiogenesis in adaptive and maladaptive right ventricular remodeling in pulmonary hypertension.

Frump AL, Bonnet S, de Jesus Perez VA, Lahm T.

Am J Physiol Lung Cell Mol Physiol. 2018 Mar 1;314(3):L443-L460. doi: 10.1152/ajplung.00374.2017. Epub 2017 Nov 2. Review.

15.

Codependence of Bone Morphogenetic Protein Receptor 2 and Transforming Growth Factor-β in Elastic Fiber Assembly and Its Perturbation in Pulmonary Arterial Hypertension.

Tojais NF, Cao A, Lai YJ, Wang L, Chen PI, Alcazar MAA, de Jesus Perez VA, Hopper RK, Rhodes CJ, Bill MA, Sakai LY, Rabinovitch M.

Arterioscler Thromb Vasc Biol. 2017 Aug;37(8):1559-1569. doi: 10.1161/ATVBAHA.117.309696. Epub 2017 Jun 15.

16.

Reduced carboxylesterase 1 is associated with endothelial injury in methamphetamine-induced pulmonary arterial hypertension.

Orcholski ME, Khurshudyan A, Shamskhou EA, Yuan K, Chen IY, Kodani SD, Morisseau C, Hammock BD, Hong EM, Alexandrova L, Alastalo TP, Berry G, Zamanian RT, de Jesus Perez VA.

Am J Physiol Lung Cell Mol Physiol. 2017 Aug 1;313(2):L252-L266. doi: 10.1152/ajplung.00453.2016. Epub 2017 May 4.

17.

In Vivo Study of Human Endothelial-Pericyte Interaction Using the Matrix Gel Plug Assay in Mouse.

Yuan K, Orcholski ME, Huang NF, de Jesus Perez VA.

J Vis Exp. 2016 Dec 19;(118). doi: 10.3791/54617.

18.

Interleukin-10-mediated regenerative postnatal tissue repair is dependent on regulation of hyaluronan metabolism via fibroblast-specific STAT3 signaling.

Balaji S, Wang X, King A, Le LD, Bhattacharya SS, Moles CM, Butte MJ, de Jesus Perez VA, Liechty KW, Wight TN, Crombleholme TM, Bollyky PL, Keswani SG.

FASEB J. 2017 Mar;31(3):868-881. doi: 10.1096/fj.201600856R. Epub 2016 Nov 30.

19.

Increased Pyruvate Dehydrogenase Kinase 4 Expression in Lung Pericytes Is Associated with Reduced Endothelial-Pericyte Interactions and Small Vessel Loss in Pulmonary Arterial Hypertension.

Yuan K, Shao NY, Hennigs JK, Discipulo M, Orcholski ME, Shamskhou E, Richter A, Hu X, Wu JC, de Jesus Perez VA.

Am J Pathol. 2016 Sep;186(9):2500-14. doi: 10.1016/j.ajpath.2016.05.016. Epub 2016 Jul 25.

20.

Novel approaches to pulmonary arterial hypertension drug discovery.

Sung YK, Yuan K, de Jesus Perez VA.

Expert Opin Drug Discov. 2016;11(4):407-14. doi: 10.1517/17460441.2016.1153625. Epub 2016 Feb 27. Review.

21.

Molecular pathogenesis and current pathology of pulmonary hypertension.

de Jesus Perez VA.

Heart Fail Rev. 2016 May;21(3):239-57. doi: 10.1007/s10741-015-9519-2. Review.

PMID:
26694808
22.

First among Equals: Nerve Growth Factor in the Pathogenesis of Pulmonary Arterial Hypertension.

de Jesus Perez VA.

Am J Respir Crit Care Med. 2015 Aug 1;192(3):274-5. doi: 10.1164/rccm.201504-0807ED. No abstract available.

PMID:
26230231
23.

Optical Coherence Tomography of Pulmonary Arterial Walls in Humans and Pigs (Sus scrofa domesticus).

Brunner NW, Zamanian RT, Ikeno F, Mitsutake Y, Connolly AJ, Shuffle E, Yuan K, Orcholski M, Lyons J, de Jesus Perez VA.

Comp Med. 2015 Jun;65(3):217-24.

24.

Perlecan heparan sulfate deficiency impairs pulmonary vascular development and attenuates hypoxic pulmonary hypertension.

Chang YT, Tseng CN, Tannenberg P, Eriksson L, Yuan K, de Jesus Perez VA, Lundberg J, Lengquist M, Botusan IR, Catrina SB, Tran PK, Hedin U, Tran-Lundmark K.

Cardiovasc Res. 2015 Jul 1;107(1):20-31. doi: 10.1093/cvr/cvv143. Epub 2015 May 6.

PMID:
25952902
25.

Suppression of endothelial CD39/ENTPD1 is associated with pulmonary vascular remodeling in pulmonary arterial hypertension.

Helenius MH, Vattulainen S, Orcholski M, Aho J, Komulainen A, Taimen P, Wang L, de Jesus Perez VA, Koskenvuo JW, Alastalo TP.

Am J Physiol Lung Cell Mol Physiol. 2015 May 15;308(10):L1046-57. doi: 10.1152/ajplung.00340.2014. Epub 2015 Mar 27.

26.

Activation of the Wnt/planar cell polarity pathway is required for pericyte recruitment during pulmonary angiogenesis.

Yuan K, Orcholski ME, Panaroni C, Shuffle EM, Huang NF, Jiang X, Tian W, Vladar EK, Wang L, Nicolls MR, Wu JY, de Jesus Perez VA.

Am J Pathol. 2015 Jan;185(1):69-84. doi: 10.1016/j.ajpath.2014.09.013. Epub 2014 Nov 6.

27.

Pumping it up! Angiogenesis and muscle deconditioning in pulmonary hypertension.

de Jesus Perez VA.

Am J Respir Crit Care Med. 2014 Aug 1;190(3):250-1. doi: 10.1164/rccm.201406-1163ED. No abstract available.

PMID:
25084260
28.

Perioperative pharmacological management of pulmonary hypertensive crisis during congenital heart surgery.

Brunner N, de Jesus Perez VA, Richter A, Haddad F, Denault A, Rojas V, Yuan K, Orcholski M, Liao X.

Pulm Circ. 2014 Mar;4(1):10-24. doi: 10.1086/674885. Review.

29.

Whole-exome sequencing reveals TopBP1 as a novel gene in idiopathic pulmonary arterial hypertension.

de Jesus Perez VA, Yuan K, Lyuksyutova MA, Dewey F, Orcholski ME, Shuffle EM, Mathur M, Yancy L Jr, Rojas V, Li CG, Cao A, Alastalo TP, Khazeni N, Cimprich KA, Butte AJ, Ashley E, Zamanian RT.

Am J Respir Crit Care Med. 2014 May 15;189(10):1260-72. doi: 10.1164/rccm.201310-1749OC.

30.

MiR-133a modulates osteogenic differentiation of vascular smooth muscle cells.

Liao XB, Zhang ZY, Yuan K, Liu Y, Feng X, Cui RR, Hu YR, Yuan ZS, Gu L, Li SJ, Mao DA, Lu Q, Zhou XM, de Jesus Perez VA, Yuan LQ.

Endocrinology. 2013 Sep;154(9):3344-52. doi: 10.1210/en.2012-2236. Epub 2013 Jun 24.

PMID:
23798596
31.

Understanding the pharmacokinetics of oral treprostinil in patients with pulmonary arterial hypertension.

de Jesus Perez VA.

J Cardiovasc Pharmacol. 2013 Jun;61(6):471-3. doi: 10.1097/FJC.0b013e318294980e. No abstract available.

PMID:
23575261
32.

MicroRNAs: promising therapeutic targets for the treatment of pulmonary arterial hypertension.

Yuan K, Orcholski M, Tian X, Liao X, de Jesus Perez VA.

Expert Opin Ther Targets. 2013 May;17(5):557-64. doi: 10.1517/14728222.2013.765863. Epub 2013 Feb 2. Review.

PMID:
23379818
33.

Loss of adenomatous poliposis coli-α3 integrin interaction promotes endothelial apoptosis in mice and humans.

de Jesus Perez VA, Yuan K, Orcholski ME, Sawada H, Zhao M, Li CG, Tojais NF, Nickel N, Rajagopalan V, Spiekerkoetter E, Wang L, Dutta R, Bernstein D, Rabinovitch M.

Circ Res. 2012 Dec 7;111(12):1551-64. doi: 10.1161/CIRCRESAHA.112.267849. Epub 2012 Sep 25.

34.

Safety and efficacy of transition from systemic prostanoids to inhaled treprostinil in pulmonary arterial hypertension.

de Jesus Perez VA, Rosenzweig E, Rubin LJ, Poch D, Bajwa A, Park M, Jain M, Bourge RC, Kudelko K, Spiekerkoetter E, Liu J, Hsi A, Zamanian RT.

Am J Cardiol. 2012 Nov 15;110(10):1546-50. doi: 10.1016/j.amjcard.2012.07.012. Epub 2012 Jul 30.

PMID:
22853986
35.

Making sense of the estrogen paradox in pulmonary arterial hypertension.

de Jesus Perez VA.

Am J Respir Crit Care Med. 2011 Sep 15;184(6):629-30. doi: 10.1164/rccm.201107-1184ED. No abstract available.

PMID:
21920924
36.

Cholinergic modulation of angiogenesis: role of the 7 nicotinic acetylcholine receptor.

Wu JC, Chruscinski A, De Jesus Perez VA, Singh H, Pitsiouni M, Rabinovitch M, Utz PJ, Cooke JP.

J Cell Biochem. 2009 Oct 1;108(2):433-46. doi: 10.1002/jcb.22270.

37.

Angina associated with left main coronary artery compression in pulmonary hypertension.

de Jesus Perez VA, Haddad F, Vagelos RH, Fearon W, Feinstein J, Zamanian RT.

J Heart Lung Transplant. 2009 May;28(5):527-30. doi: 10.1016/j.healun.2008.12.008. Epub 2009 Feb 20.

PMID:
19416787
38.

Bone morphogenetic protein 2 induces pulmonary angiogenesis via Wnt-beta-catenin and Wnt-RhoA-Rac1 pathways.

de Jesus Perez VA, Alastalo TP, Wu JC, Axelrod JD, Cooke JP, Amieva M, Rabinovitch M.

J Cell Biol. 2009 Jan 12;184(1):83-99. doi: 10.1083/jcb.200806049.

39.

An antiproliferative BMP-2/PPARgamma/apoE axis in human and murine SMCs and its role in pulmonary hypertension.

Hansmann G, de Jesus Perez VA, Alastalo TP, Alvira CM, Guignabert C, Bekker JM, Schellong S, Urashima T, Wang L, Morrell NW, Rabinovitch M.

J Clin Invest. 2008 May;118(5):1846-57. doi: 10.1172/JCI32503.

Supplemental Content

Loading ...
Support Center